New method to deliver antibiotics for treating severe gum disease
Controlled antibiotic delivery vehicle for treatment of aggressiveperiodontitis
This study is testing a new way to deliver antibiotics specifically for people with aggressive periodontitis caused by certain bacteria, aiming to make treatments more effective by targeting the harmful toxins and helping your immune system work better.
Quick facts
| Grant type | R21 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Lehigh University NIH-funded |
| Lab location | 1 site (Bethlehem, United States) |
| Project ID | NIH-10794379 on NIH RePORTER |
What this research studies
This research focuses on developing a specialized liposome-based delivery system for antibiotics aimed at treating aggressive periodontitis caused by the bacteria Aggregatibacter actinomycetemcomitans. The approach targets a specific toxin produced by the bacteria, which impairs the immune response, making traditional treatments less effective. By optimizing the liposome composition, the researchers aim to ensure that antibiotics are released only when the harmful bacteria are present, potentially improving treatment outcomes. Patients may benefit from a more effective and targeted therapy that enhances their immune response and promotes healing.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals, particularly adolescents, diagnosed with aggressive periodontitis linked to Aggregatibacter actinomycetemcomitans.
Not a fit: Patients with mild forms of periodontitis or those not infected with Aggregatibacter actinomycetemcomitans may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatments for patients suffering from aggressive periodontitis.
How similar studies have performed: While the approach of using liposome-based delivery systems is promising, this specific application targeting LtxA in periodontitis is relatively novel and has not been extensively tested in prior studies.
Where this research is happening
Bethlehem, United States
- Lehigh University — Bethlehem, United States (Active)
Researchers
- Principal investigator: Brown, Angela C. — Lehigh University
- Study coordinator: Brown, Angela C.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.